Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH) is a progressive liver disease associated with liver-related complications and death. The efficacy and safety of tirzepatide, an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, in patients with MASH and moderate or severe fibrosis is unclear. METHODS: We conducted a phase 2, dose-finding, multicenter, double-blind, randomized, placebo-controlled trial involving participants with biopsy-confirmed MASH and stage F2 or F3 (moderate or severe) fibrosis. Participants were randomly assigned to receive once-weekly subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 52 weeks. The primary end point was resolution of MASH without worsening of fibrosis at 52 weeks. A key secondary end point was an improvement (decrease) of at least one fibrosis stage without worsening of MASH. RESULTS: Among 190 participants who had undergone randomization, 157 had liver-biopsy results at week 52 that could be evaluated, with missing values imputed under the assumption that they would follow the pattern of results in the placebo group. The percentage of participants who met the criteria for resolution of MASH without worsening of fibrosis was 10% in the placebo group, 44% in the 5-mg tirzepatide group (difference vs. placebo, 34 percentage points; 95% confidence interval [CI], 17 to 50), 56% in the 10-mg tirzepatide group (difference, 46 percentage points; 95% CI, 29 to 62), and 62% in the 15-mg tirzepatide group (difference, 53 percentage points; 95% CI, 37 to 69) (P<0.001 for all three comparisons). The percentage of participants who had an improvement of at least one fibrosis stage without worsening of MASH was 30% in the placebo group, 55% in the 5-mg tirzepatide group (difference vs. placebo, 25 percentage points; 95% CI, 5 to 46), 51% in the 10-mg tirzepatide group (difference, 22 percentage points; 95% CI, 1 to 42), and 51% in the 15-mg tirzepatide group (difference, 21 percentage points; 95% CI, 1 to 42). The most common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity. CONCLUSIONS: In this phase 2 trial involving participants with MASH and moderate or severe fibrosis, treatment with tirzepatide for 52 weeks was more effective than placebo with respect to resolution of MASH without worsening of fibrosis. Larger and longer trials are needed to further assess the efficacy and safety of tirzepatide for the treatment of MASH. (Funded by Eli Lilly; SYNERGY-NASH ClinicalTrials.gov number, NCT04166773.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The primary outcome for all three studies was resolution of fatty liver disease without worsening of fibrosis, and significant improvements were noted.”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“tirzepatide led to an increased proportion of participants reaching an improvement in fibrosis by at least one stage.83”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [83]
In the citing paper
“Apart from improvements in multiple cardiometabolic risk factors, tirzepatide also improves various obesity-related complications such as obstructive sleep apnoea (OSA), metabolic dysfunction-associated steatohepatitis (MASH) and heart failure with preserved ejection fraction [28–30].”
From Triple Agonism Based Therapies for Obesity (2025) · cites this paper as [29]
In the citing paper
“Other recent analyses have revealed survodutide, tirzepatide, and retatrutide to each significantly reduce liver fat with no evidence of worsening in markers of liver fibrosis.77, 78, 79”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [79]
In the citing paper
“tirzepatide also increased the proportion of patients achieving at least one-stage fibrosis improvement without MASH worsening (approximately 51–55% vs. 30% with placebo).”
From Strategies to promote liver fibrosis amelioration with involvement of restorative macrophages (2026) · cites this paper as [224]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationA multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000520 · Cited by 3,476
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Self-citationVilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis
Harrison, S. A., Bedossa, P., Guy, C. D., Schattenberg, J. M., Loomba, R., Taub, R., Labriola, D., Moussa, S. E., Neff, G. W., Rinella, M. E., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309000 · Cited by 2,084
Self-citationA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Self-citation
Cited by
Items 401–500 of 999
Sugawara, T., Hitaka, K., Matsumoto, M., Nakamura, S., Kobayashi, R., Kandori, H., & Nio, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-24927-3 · Cited by 5
Liver disease in people living with HIV infection: a changing landscape
Lee, F., & Bansal, M. B. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01149-6 · Cited by 8
Correa, T. L., & Duong, N. K. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i11.112573 · Cited by 5
Metabolic syndrome after liver transplantation: A silent threat to long-term success
Chan, S., Lee, J. S., Karki, P., Laryea, M. A., Huang, J. H., Lim, N., & Twohig, P. A. (2025) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v16.i4.111073 · Cited by 7
Fu, R., Zhang, F., Fu, J., Li, Y., Zhu, X., Ding, Q., & Zhu, Y. Z. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.163 · Cited by 7
Tentolouris, A., & Ntanasis‐Stathopoulos, I. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70394 · Cited by 4
MASLD as a complication of obesity must include liver risk stratification
Rinella, M. E., Sanyal, A. J., Loomba, R. S., Noureddin, M., Bansal, M. B., Newsome, P. N., & Ratziu, V. (2026) · Nature Medicine · doi:10.1038/s41591-025-04130-7 · Cited by 4
Self-citationStokar, J., & Dresner–Pollak, R. (2026) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70121 · Cited by 5
Siranart, N., Thompson, C. C., & Jirapinyo, P. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000871 · Cited by 8
Role of endogenous incretin hormones, GLP-1 and GIP, in cardiovascular physiology
Trivedi, K., & Dolinsky, V. W. (2026) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0163 · Cited by 7
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101445 · Cited by 12
iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.70167 · Cited by 5
Brouwer, W. P., Vonghia, L., Thiele, M. S., Schattenberg, J. M., Anastasiou, F., Beckmann, S., Bugianesi, E., Castéra, L., Caussy, C., Cordie, A., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101798 · Cited by 12
Self-citationKhalifa, O., & Arredouani, A. (2026) · Pharmaceuticals · doi:10.3390/ph19030408 · Cited by 8
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Cetiner, S. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s594898 · Cited by 7
Albor, C., Anyiam, O., Boyle, L., Makaronidis, J., Tan, R. J. L., Iftikhar, S., Burzić, A., Lajeunesse‐Trempe, F., Stanley, M., Bhatti, A. I., et al. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00707-6 · Cited by 5
Management of MASLD/MASH: challenges, innovations, and the future of patient-centered care in Japan
Seko, Y., & Yamaguchi, K. (2026) · Journal of Gastroenterology · doi:10.1007/s00535-026-02401-9 · Cited by 4
Li, J., Liang, J., Zhang, W., He, J., & Ye, X. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01872-6 · Cited by 5
MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues
Ha, S., Zhang, X., Lan-juan, L., & Yu, J. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.04.048 · Cited by 8
Beyond weight loss: multisystem benefits of obesity medications
Savas, M., Kuckuck, S., Boon, M. R., & van Rossum, E. F. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00100-2 · Cited by 5
Jin, J., & Yang, C. C.-K. (2026) · Metabolites · doi:10.3390/metabo16070489 · Cited by 8
MASLD and the cardiovascular-kidney-liver-metabolic syndrome
Angelidi, A. M., Boutari, C., Kokkorakis, M., Stefanakis, K., Mikhailidis, D. P., Jacob, G., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag023 · Cited by 7
Karagiannakis, D. S., Stefanaki, K., Paschou, S. Α., Papatheodoridi, Μ., Tsiodras, S., & Παπάνας, Ν. (2024) · HORMONES · doi:10.1007/s42000-024-00625-z · Cited by 5
Safety Choice Drivers of the Coming Treatment Options for Non‐Cirrhotic Metabolic Steatohepatitis
Mangia, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70271 · Cited by 4
Diagnosis and management of metabolic dysfunction associated steatotic liver disease
Musso, G., Lassen, A., Banda, L., Maher, J. J., & Gambino, R. (2025) · BMJ · doi:10.1136/bmj-2025-084950 · Cited by 6
Askeland-Gjerde, D. E., Westlye, L. T., Andersson, P., Korbmacher, M., de Lange, A. G., van der Meer, D., Smeland, O. B., Halvorsen, S., Andreassen, O. A., & Gurholt, T. P. (2025) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2025.100488 · Cited by 5
Two Trials of Therapeutics for MASH with Liver Fibrosis
Mei, Z., Pu, J., & Shao, Z. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2411003 · Cited by 4
Jayabalan, D., Dhakal, S., Chandra, J., Fasser, D. A., Jeffrey, G. P., Garas, G., Vilar-Gomez, E., Calzadilla-Bertot, L., & Adams, L. A. (2026) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003918 · Cited by 3
7. Management of metabolic dysfunction-associated steatotic liver disease (MASLD) in type 2 diabetes
Colagiuri, S., & Ceriello, A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112151 · Cited by 3
Godwin, K. M., Grigoryan, L., Thrift, A. P., Duong, H. T., Kanwal, F., Giardina, T. D., Kadiyala, H., Zimolzak, A. J., Patidar, K. R., & El‐Serag, H. B. (2025) · BMC Health Services Research · doi:10.1186/s12913-025-12737-2 · Cited by 3
Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD
Eppler, N., Jones, E., Ahamed, F., & Zhang, Y. (2025) · Livers · doi:10.3390/livers5030033 · Cited by 5
Larsen, A. T., Melander, S. A., Mohamed, K. E., Petersen, E. A., Benmarce, M., Karsdal, M. A., & Henriksen, K. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118388 · Cited by 3
Obstructive Sleep Apnoea Treatments—Where Are We Now?
Luu, S., Lee, D., & Yee, B. J. (2025) · Respirology · doi:10.1111/resp.70109 · Cited by 3
Arredouani, A. (2025) · Diabetologia · doi:10.1007/s00125-025-06527-y · Cited by 3
Overweight and obesity in metabolic syndrome
Nedogoda, S. V., & Васильевна, Ц. О. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6535 · Cited by 5
Kaya, E., Yilmaz, Y., & Alkhouri, N. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2566258 · Cited by 6
Davis, J. P. E., Henry, Z., Sharma, P., Tsunoda, S. M., Han, H., Orandi, B. J., Heimbach, J. K., Schulman, A. R., Tincopa, M. A., Argo, C. K., et al. (2025) · American Journal of Transplantation · doi:10.1016/j.ajt.2025.10.008 · Cited by 3
Longsomboon, R., Kachornvitaya, P., Prasoppokakorn, T., Treeprasertsuk, S., Boonchaya‐anant, P., Klaikaew, N., & Udomsawaengsup, S. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04482-x · Cited by 3
Zhu, B. J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1753393 · Cited by 3
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Bariatric Surgery in the Era of GLP1RA: A Narrative Review
Muhundan, M., & Dash, S. (2026) · Advances in Therapy · doi:10.1007/s12325-026-03494-7 · Cited by 2
Ogbu, C. E., Ogbu, S. C., Ogbu, C. P., & Umerah, C. (2026) · iLiver · doi:10.1016/j.iliver.2026.100222 · Cited by 3
Hu, W., Gu, M., Li, H., Li, H., Kan, J., Zhang, L., Ding, Q., & Zhu, Y. Z. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100125 · Cited by 5
Facciorusso, A., Giannini, E. G., Tacelli, M., Zanetto, A., Spada, C., Boskoski, I., Furnari, M., Pennisi, G., Capurso, G., Vitello, A., et al. (2026) · Digestive and Liver Disease · doi:10.1016/j.dld.2026.02.018 · Cited by 3
Evaluating the therapeutic impact of tirzepatide in people with partial lipodystrophy
Mandour, M. O., Stears, A. J., van der Klaauw, A. A., Flanagan, C., Gaff, L., Jenkins, C., & Savage, D. B. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag126 · Cited by 4
Maruyama, F., Kitsunai, H., Kitao, N., Wakabayashi, Y., Ito, M., Kurihara, H., Yamamoto, K., Takeuchi, J., Abiko, A., Homma, R., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70734 · Cited by 4
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Cobbold, J., Miller, H., Hallsworth, K., Manousou, P., Marjot, T., Allison, M. E., Anstee, Q. M., Armstrong, M., Avery, L., Azzu, V., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00077-4 · Cited by 5
Akuta, N., Kogiso, T., Ikejima, K., Otsuka, M., Kawaguchi, T., Kawanaka, M., Takahashi, H., Tamaki, N., Nakagawa, H., 疋田隼人, et al. (2026) · Hepatology Research · doi:10.1111/hepr.70188 · Cited by 8
Self-citationRivas, J. A., Murphy, A. C., Prasad, P., Yahia, M. S., Goitom, S. S., Romero, A. S., Enriquez, C. M., Maes, B. B., Akepati, P. R., Garcia, M. A., et al. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156652 · Cited by 5
Tang, M., Ma, Y., & Wang, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1829315 · Cited by 3
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Newer and novel antidiabetic drug classes across the cardiovascular–kidney–metabolic continuum
Stefanakis, K., Karakasis, P., Vasdeki, D., Popovic, D. S., Patoulias, D., Rizzo, M., & Mantzoros, C. S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnag022 · Cited by 6
Pharmacological treatment of MASH
Stefan, N., & Targher, G. (2026) · Diabetologia · doi:10.1007/s00125-026-06796-1 · Cited by 6
The new era of MASH pharmacotherapy: a comprehensive review of FDA-approved and emerging agents
Qasim, A., Alataa, R., Veena, F., & Shehi, E. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1850915 · Cited by 4
Kitsios, K., Trakatelli, C., Antza, C., Triantafyllou, Α., Sarigianni, M., & Kotsis, V. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0059 · Cited by 3
Shumbayawonda, E., Beyer, C., Alonso, B. D. C., Hidalgo-Tobón, S., López-Martı́nez, B., Klünder‐Klünder, M., Miranda‐Lora, A. L., Thomas, E. L., Bell, J. D., Breen, D. J., et al. (2024) · Children · doi:10.3390/children11101230 · Cited by 3
Treatment of type 2 diabetes with MASLD: new evidence for personalised medicine
Caussy, C. (2024) · Gut · doi:10.1136/gutjnl-2024-333485 · Cited by 4
Choi, R., Vemuri, J. P., Poloju, A., Raj, R., Mehta, A., Asgharpour, A., Siddiqui, M. S., & Majety, P. (2025) · Endocrines · doi:10.3390/endocrines6020027 · Cited by 4
Evolving Role of GLP-1 Therapies in Liver Disease
Lindsay, M., Arndt, G., Wieland, A. C., & Jensen, T. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-00988-2 · Cited by 3
Arai, T., Atsukawa, M., Nagao, C., Yamada, Z., Rokugo, T., Suzuki, K. M., Kitamura, M., Higashi, T., Koyano, K., Hasegawa, Y., et al. (2025) · Hepatology Research · doi:10.1111/hepr.14241 · Cited by 8
Luong, T. V., Tran, H., Thi, B. N. C., Vu, H. M., Le, T., Le, T., Thi, H. N., Nguyen, H. M., Doan, T. C., Ho, A. B., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i7.107751 · Cited by 5
Zatta, R., da Silva, L. S., Felga, G. E. G., & Pimentel, C. F. M. G. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107837 · Cited by 3
Kim, J. W., Raggi, P., Carreau, A., Wharton, S., CHENG, A. Y. Y., & Swain, M. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70117 · Cited by 6
Sato‐Espinoza, K., Vierkant, R. A., Chotiprasidhi, P., Vairo, F. P. E., Tian, S., Ma, J., O’Brien, D. R., Lazaridis, K. N., Dlugosch, C., Schneider, C. V., et al. (2025) · Liver International · doi:10.1111/liv.70300 · Cited by 5
Tirzepatide in Treating Metabolic Disorders
Wei, S., & Xu, S. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100023 · Cited by 4
Metabolic dysfunction-associated steatotic liver disease
Chen, C., & Liao, D.-M. (2024) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-24-00019 · Cited by 3
Williams, D. M., Nagaraj, J., Stephens, J. W., & Min, T. (2025) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2025.21.1.4 · Cited by 3
Optimizing liver transplant candidacy in patients with cirrhosis and obesity
Ha, N. B., Heimbach, J. K., & Hameed, B. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000609 · Cited by 3
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica · doi:10.1016/j.medcli.2025.106951 · Cited by 6
Sebastiani, G., Raggi, P., & Guaraldi, G. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.06.075 · Cited by 8
Marcondes‐de‐Castro, I. A., Marinho, T. D. S., Águila, M. B., & Mandarim‐de‐Lacerda, C. A. (2025) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000002683 · Cited by 4
MASLD in the cardiovascular–kidney–metabolic health framework: what does it add to the table?
Ha, K. H., Kim, D. J., & Lee, H. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf549 · Cited by 5
Incretin-based therapies for liver disease
Kotsiliti, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00961-w · Cited by 2
Elmakki, E. E. (2024) · Cureus · doi:10.7759/cureus.66074 · Cited by 2
Mouse Models for the Study of Liver Fibrosis Regression In Vivo and Ex Vivo
Schönke, M., & Rensen, P. C. N. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00212 · Cited by 13
Challenges in the management of MetALD after liver transplantation
Cucco, M., Becchetti, C., Scaravaglio, M., Dispinzieri, G., Bolis, F., Bagalà, L., Strollo, M., Orlando, M., Perricone, G., Mazzarelli, C., et al. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.144 · Cited by 2
Fármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Lin, J., Green, V., Sohal, A., & Roytman, M. M. (2025) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000002234 · Cited by 3
Two Cases of Diabetes Remission through Temporary Tirzepatide Treatment
Sawamura, T., Ohmori, A., Kometani, M., Karashima, S., & Yoneda, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5779-25 · Cited by 4
Cai, Y., Xie, S., Xu, L., Chen, J., & Cai, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178088 · Cited by 2
Attia, A. M., Zavareh, M. S. R., Yeo, Y. H., Kwak, M., Kim, H., Noureddin, M., & Yang, J. D. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000806 · Cited by 2
Nowak, M. A., Núñez, L. M., Hill, C., Pagliaro, T., McGonigle, J., Niglas, M., Bell-Bradford, C., Robson, M. D., Thomaides-Brears, H. B., Thomas, E. L., et al. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05170-w · Cited by 3
Lingow, S. E., Carris, N. W., Clements, J. N., Courtney, L. A., Lennon, A., Sherrill, C. H., & Dril, E. V. (2025) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.70111 · Cited by 5
From abdominal adiposity to liver fibrosis: Expanding promise of semaglutide for Asian Indians
Ghosh, A., & Misra, A. (2025) · Indian Journal of Gastroenterology · doi:10.1007/s12664-025-01881-6 · Cited by 2
Stefanakis, K., Mingrone, G., George, J., & Mantzoros, C. S. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.10.029 · Cited by 3
Barenbaum, S. R., Aras, M., Kashyap, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf641 · Cited by 2
Feng, J. N., Chen, Y., & Jin, T. (2025) · Metabolism and Diseases · doi:10.1016/j.metdis.2025.100001 · Cited by 3
Wood, E. M., Akande, R. O., Iqbal, I., & Albert, S. G. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70314 · Cited by 2
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
Revolutionizing Diabetes Care: From Tech to Therapeutics
Aktürk, H. K., WATERMAN, L. A., & Cobry, E. C. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580423 · Cited by 2
Pharmacologic approach to metabolic dysfunction and related diseases: focus on liver aspects
Piazzolla, V., Napolitano, A., & Mangia, A. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.152 · Cited by 2
Wu, J., Lin, Y., Hsu, W., Liu, T.-H., Tsai, Y., Huang, P., Chuang, M.-H., Yu, T., & Lai, C. (2026) · Hepatology International · doi:10.1007/s12072-025-11021-z · Cited by 3
Liver–pancreas communication in disease and drug development
Jia, Y., Zhu, Q., Pan, Q., Lu, G., & Xiao, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.018 · Cited by 3
Management of obesity in advanced chronic liver disease
Caussy, C., & Francque, S. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101749 · Cited by 3
Zheng, N., 涂龙芳, Xu, P., Chen, R., Lu, J., Dai, W., Lin, Y., Ouyang, J., Qiu, J., Wang, Y., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03845 · Cited by 2
Slaton, R. M., Iranikhah, M. G., & White, C. W. (2026) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2026.100032 · Cited by 4
Fan, Y., Gong, S., & Wang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1709404 · Cited by 3
Nowak, M. Z., Núñez, L. M., Pagliaro, T., Robson, M. D., Duncker, C. M., Kaplan, L. M., Heymsfield, S., Thomaides-Brears, H. B., Bell, J. D., & Thomas, E. L. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02037-y · Cited by 3
Metadata
- Authors
- Loomba, R., Hartman, M. L., Lawitz, E. J., Vuppalanchi, R., Boursier, J., Bugianesi, E., Yoneda, M., Behling, C., Cummings, O. W., Tang, Y., Brouwers, B., Robins, D. A., Nikooie, A., Bunck, M. C., Haupt, A., & Sanyal, A. J.
- Affiliations
- University of California San Diego (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-07-25
- Volume
- 391
- Issue
- 4
- Pages
- 299-310
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4399461049
- Cited by
- 1,005
- References
- 37
- Citations by year
- 2026: 458 · 2025: 433 · 2024: 114
- FWCI
- 306.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- tirzepatide, nonalcoholic steatohepatitis, liver fibrosis, GIP/GLP-1 receptor agonist, fibrosis regression, dose-response relationship, liver biopsy, non-alcoholic fatty liver disease, obesity, type 2 diabetes, weight loss, drug safety, adverse events, liver complications, hepatocellular carcinoma, liver cirrhosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-2 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Fatty Liver, Female, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Liver, Liver Cirrhosis, Male, Middle Aged
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.